Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

(2014) Keith T Flaherty et al.   LANCET ONCOLOGY

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

(2013) Miranda J. Payne et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutaneous melanoma

(2013) Alexander MM Eggermont et al.   LANCET

Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

(2012) Jean Jacques Grob et al.   EUROPEAN JOURNAL OF CANCER

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

(2012) Alexander M.M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

(2012) Beth Sherrill et al.   OncoTargets and Therapy

A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

(2011) Lili Mao et al.   EUROPEAN JOURNAL OF CANCER

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

(2011) Johan Hansson et al.   LANCET ONCOLOGY

Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial

(2010) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases

(2010) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

(2009) Susan Halabi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node–Negative Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

(2009) Dimitrios Pectasides et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

(2009) Stefan Michiels et al.   LANCET ONCOLOGY

Adjuvant low-dose interferon  2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

(2008) C. Garbe et al.   ANNALS OF ONCOLOGY

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

(2008) Tomasz Burzykowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET